New hope for rare fat disorder: drug trial targets blood sugar and fat levels
NCT ID NCT07220785
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 29 times
Summary
This study tests a new drug, mibavademab, in people with generalized lipodystrophy (GLD), a rare condition where the body lacks fat tissue, leading to serious metabolic problems. The goal is to see if the drug can improve blood sugar and fat levels safely. About 28 children and adults will take part in this Phase 3 trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED LIPODYSTROPHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UT Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.